“Growth.” During the meeting, unions expressed concern as regards employment and working conditions in the sector. There are more and more mergers, buyouts and restructurings, notably to face the loss of patents, between 2010 and 2012, and the national policy of cutting health costs. Novartis, the Swiss group, recently announced a program cutting 2,000 jobs and shutting down five sites in Switzerland and Italy. Pfizer, American world leader, is planning 6,000 job cuts by 2015 and Merck group is planning 13,000 fewer jobs within the next three years. During the meeting on October 28, unions looked into the sector’s problems related to drug licenses and health policies, which tend to restrict drug spending. Nevertheless, Kemal Özkan, ICEM Director of Industry and Corporate Affairs, says that global pharmaceutical sales are in a growth trend. “The sector is in durable growth. It was 8 percent in 2004 and forecasts are planning 5-7% up to 2015.” Sales are notably up in emerging countries like China, the world’s third-largest market in the sector.
censes and health policies, which tend to restrict drug spending. Nevertheless, Kemal Özkan, ICEM Director of Industry and Corporate Affairs, says that global pharmaceutical sales are in a growth trend. “The sector is in durable growth. It was 8 percent in 2004 and forecasts are planning 5-7% up to 2015.” Sales are notably up in emerging countries like China, the world’s third-largest market in the sector.
Platform. Considering that workers are the first to pay the price of the national pol
…Do you have information to share with us?